Niels Vande Casteele (N Vande Casteele)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 32

Top Venues

Alimentary pharmacology & therapeutics

Gut

Therapeutic drug monitoring

Nature reviews. Gastroenterology & hepatology

University of California San Diego

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of California San Diego Sep 01 2017

United States

Assistant Professor :: Department of Medicine

Publications

Niels Vande Casteele, Lili Yang, Iwona Dobler, Christian Agboton, Teresa McRorie Osborn, Ajit Suri, Dirk Lindner, Glennda M Smithson
Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay. Therapeutic drug monitoring 45 (2) (2023)
Niels Vande Casteele, Lili Yang, Iwona Dobler, Christian Agboton, Teresa McRorie Osborn, Ajit Suri, Dirk Lindner, Glennda M Smithson
Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay. Therapeutic drug monitoring 45 (2) (2023)
Bram Verstockt, Azucena Salas, Bruce E Sands, Clara Abraham, Haim Leibovitzh, Markus F Neurath, Niels Vande Casteele, null null
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology (2023)
Niels Vande Casteele, Lili Yang, Iwona Dobler, Christian Agboton, Teresa McRorie Osborn, Ajit Suri, Dirk Lindner, Glennda M Smithson
Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay. Therapeutic drug monitoring (2023)
Niels Vande Casteele, Lili Yang, Iwona Dobler, Christian Agboton, Teresa McRorie Osborn, Ajit Suri, Dirk Lindner, Glennda M Smithson
Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay. Therapeutic drug monitoring 45 (2) (2023)
Niels Vande Casteele, William J Sandborn, Brian G Feagan, Séverine Vermeire, Parambir S Dulai, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark T Osterman, Maria Rosario, Teresa McRorie Osborn, Julian Panes, Dirk Lindner, Christian Agboton
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Alimentary pharmacology & therapeutics 56 (3) (2022)
Niels Vande Casteele, Brian G Feagan, Douglas C Wolf, Anca Pop, Mohamed Yassine, Sara N Horst, Timothy E Ritter, William J Sandborn
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflammatory bowel diseases 27 (8) (2022)
Bram Verstockt, Stefania Vetrano, Azucena Salas, Shadi Nayeri, Marjolijn Duijvestein, Niels Vande Casteele, null null
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology 19 (6) (2022)
Rocio Sedano, Malcolm Hogan, Tran M Nguyen, Joshua Chang, G Y Zou, John K Macdonald, Niels Vande Casteele, Jurij Hanzel, Eileen Crowley, Robert Battat, Parambir S Dulai, Siddharth Singh, Geert D'Haens, William Sandborn, Brian G Feagan, Christopher Ma, Vipul Jairath
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. Journal of Crohn's & colitis (2021)
Amy Hemperly, Marla C Dubinsky, Andres Yarur, Anita Afzali, Stephen Hanauer, Subra Kugathasan, Millie D Long, Shervin Rabizadeh, Robbyn Sockolow, Lauren Okada, Anjali Jain, Maria T Abreu, Niels Vande Casteele
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring. Crohn's & colitis 360 3 (3) (2021)
David Chen, Clifton Fulmer, Ilyssa O Gordon, Sana Syed, Ryan W Stidham, Niels Vande Casteele, Yi Qin, Katherine Falloon, Benjamin L Cohen, Robert Wyllie, Florian Rieder
Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know. Journal of Crohn's & colitis (2021)
Bryan Linggi, Vipul Jairath, Guangyong Zou, Lisa M Shackelton, Dermot P B McGovern, Azucena Salas, Bram Verstockt, Mark S Silverberg, Shadi Nayeri, Brian G Feagan, Niels Vande Casteele
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. Scientific reports 11 (1) (2021)
Amy Hemperly, Marla C Dubinsky, Andres Yarur, Anita Afzali, Stephen Hanauer, Subra Kugathasan, Millie D Long, Shervin Rabizadeh, Robbyn Sockolow, Lauren Okada, Anjali Jain, Maria T Abreu, Niels Vande Casteele
Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring. Crohn's & colitis 360 3 (3) (2021)
Jurij Hanžel, Christopher Ma, Niels Vande Casteele, Reena Khanna, Vipul Jairath, Brian G Feagan
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs 81 (3) (2021)
Pavine L C Lefevre, Parambir S Dulai, Zhongya Wang, Leonardo Guizzetti, Brian G Feagan, Anca Pop, Mohamed Yassine, Lisa M Shackelton, Vipul Jairath, William J Sandborn, Niels Vande Casteele
A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 36 (1) (2021)
Pavine L C Lefevre, Lisa M Shackelton, Niels Vande Casteele
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (5) (2020)
Niels Vande Casteele, Vipul Jairath
Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply. Alimentary pharmacology & therapeutics 50 (1) (2020)
Niels Vande Casteele, Abhijeet Jakate, Brian McNamee, William J Sandborn
Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. British journal of clinical pharmacology 87 (3) (2020)
Edward Yang, Nicola Panaccione, Natalie Whitmire, Parambir S Dulai, Niels Vande Casteele, Siddharth Singh, Brigid S Boland, Angelina Collins, William J Sandborn, Remo Panaccione, Robert Battat
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Alimentary pharmacology & therapeutics 51 (11) (2020)
Azucena Salas, Cristian Hernandez-Rocha, Marjolijn Duijvestein, William Faubion, Dermot McGovern, Severine Vermeire, Stefania Vetrano, Niels Vande Casteele
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nature reviews. Gastroenterology & hepatology 17 (6) (2020)
Christopher Ma, Jeffrey K Lee, Anish R Mitra, Anouar Teriaky, Daksh Choudhary, Tran M Nguyen, Niels Vande Casteele, Reena Khanna, Remo Panaccione, Brian G Feagan, Vipul Jairath
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Alimentary pharmacology & therapeutics 50 (1) (2019)
Niels Vande Casteele, Jun Oyamada, Chisato Shimizu, Brookie M Best, Edmund V Capparelli, Adriana H Tremoulet, Jane C Burns
Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. Clinical pharmacokinetics 57 (12) (2019)
Gregor Novak, Toer W Stevens, Tanja Van Viegen, Peter Bossuyt, Borut Štabuc, Jenny Jeyarajah, Guangyong Zou, Ingrid C Gaemers, Trevor D McKee, Fred Fu, Lisa M Shackelton, Reena Khanna, Gijs R van den Brink, William J Sandborn, Brian G Feagan, Rish K Pai, Vipul Jairath, Niels Vande Casteele, Geert D'Haens
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Alimentary pharmacology & therapeutics 49 (11) (2019)
Amy Hemperly, Niels Vande Casteele
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical pharmacokinetics 57 (8) (2019)
Robert Battat, Parambir S Dulai, Vipul Jairath, Niels Vande Casteele
A product review of vedolizumab in inflammatory bowel disease. Human vaccines & immunotherapeutics 15 (10) (2019)
Siddharth Singh, Parambir S Dulai, Niels Vande Casteele, Robert Battat, Mathurin Fumery, Brigid S Boland, William J Sandborn
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Alimentary pharmacology & therapeutics 50 (8) (2019)
Christopher Ma, Leonardo Guizzetti, R Panaccione, Richard N Fedorak, Rish K Pai, C E Parker, T M Nguyen, R Khanna, Niels Vande Casteele, Geert R A M D'Haens, William J Sandborn, Brian G Feagan, Vipul Jairath
Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Alimentary pharmacology & therapeutics 47 (12) (2018)
Niels Vande Casteele, B G Feagan, S Vermeire, M Yassine, J Coarse, G Kosutic, W J Sandborn
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Alimentary pharmacology & therapeutics 47 (2) (2017)
Niels Vande Casteele, Reena Khanna
Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharmaceutical research 34 (8) (2017)
Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut 67 (5) (2017)
Niels Vande Casteele, A Gils
Editorial: variability in adalimumab trough and peak serum concentrations. Alimentary pharmacology & therapeutics 45 (11) (2017)
Niels Vande Casteele
Assays for measurement of TNF antagonists in practice. Frontline gastroenterology 8 (4) (2016)
Thomas Billiet, Niels Vande Casteele, Thomas Van Stappen, Fred Princen, Sharat Singh, Ann Gils, Marc Ferrante, Gert Van Assche, Isabelle Cleynen, Severine Vermeire
Immunogenicity to infliximab is associated with HLA-DRB1. Gut 64 (8) (2015)
Filip Baert, Venkateswarlu Kondragunta, Steven Lockton, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, Konstantinos Karmiris, Marc Ferrante, Ann Gils, Séverine Vermeire
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut 65 (7) (2015)
Niels Vande Casteele, Reena Khanna, Barrett G Levesque, Larry Stitt, G Y Zou, Sharat Singh, Steve Lockton, Scott Hauenstein, Linda Ohrmund, Gordon R Greenberg, Paul J Rutgeerts, Ann Gils, William J Sandborn, Séverine Vermeire, Brian G Feagan
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 64 (10) (2014)

Niels Vande Casteele.css-eqlu8i{font-size:small;padding-left:4px;} (N Vande Casteele)

Publication Activity (10 Years)

Top Topics

Top Venues

Niels Vande Casteele (N Vande Casteele)